• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ImmunityBio (IBRX) Faces A Valuation Test Following Thoracic Symposium Attention

    Simply Wall St·10/08/2026 10:29:44
    Listen to the news

    ImmunityBio (IBRX) heads into the Thoracic Rare Cancer Symposium in Ottawa on 2 October 2026 with fresh attention on its immunotherapy pipeline and what upcoming data could mean for long term expectations.

    ImmunityBio’s recent 30 day share price return of 20.67% and year to date share price return of 382.67% point to strong momentum. At the same time, a 1 year total shareholder return of 285.38% and 3 year total shareholder return of more than 6x keep longer term investors firmly focused on how new clinical data might affect perceived risk and future expectations.

    Scan ImmunityBio’s recent run against a curated field of late-stage stories by lining it up beside 20 high quality undiscovered gems gaining fresh attention from investors ahead of major catalysts.

    After a 20.67% move in 30 days and a market value near US$10.27b, ImmunityBio’s profile looks very different compared with where it started this year. Does that recent surge still leave enough potential upside to justify the risk?

    Most Popular Narrative: 25% Undervalued

    ImmunityBio last closed at $9.75 while the most followed narrative anchors fair value at $13.00. Thoracic Symposium data therefore arrives against a backdrop where the story already assumes a lot of future execution.

    The rapid global expansion of ANKTIVA into 33 countries, including the U.S., EU, U.K., and Saudi Arabia, together with commercial partners like Accord and regional distributors, sets up a much larger treated patient base over time, which is directly tied to future product revenue growth.

    The broad use of checkpoint inhibitors across many tumor types has created a large pool of patients with limited options after checkpoint failure. ANKTIVA combinations targeting this setting, such as in QUILT-3.055, address an existing treatment gap that could influence future revenue and potentially support higher utilization per patient.

    See why 15 investors see ImmunityBio as 25% undervalued.

    The narrative uses a discount rate of about 7.4% and incorporates ambitious assumptions on revenue and margin expansion before arriving at that $13.00 figure. With analysts expecting revenue to grow rapidly and net profit margin to shift from deep losses toward more typical biotech levels over time, the framework effectively asks whether ImmunityBio can turn its current $992.36m loss into sustained earnings that justify a higher valuation.

    Those expectations sit on top of analyst forecasts that revenue could expand at 49.5% per year and that earnings growth could run at 70.26% per year as the business is projected to move into profitability within three years. The same story also includes future dilution, with shares on issue expected to rise by 7% annually, and still concludes that the present price is below what those future cash flows support when discounted at 7.4%.

    At the same time, Simply Wall St’s DCF output points to a much higher future cash flow value of $45.83 per share compared with the recent $9.75 close, which is a very large gap. That DCF view relies on long term cash generation that is not yet visible in current results, given reported revenue of $165.79m and a sizeable net loss, so readers may want to stress test the trial, pricing and adoption assumptions that would need to hold to bridge that distance.

    Result: Fair Value of $13.00 (UNDERVALUED)

    Still, if ImmunityBio’s non bladder programs disappoint or regulators push back on new ANKTIVA indications, today’s growth heavy narrative could quickly lose traction.

    Find out about the key risks to this ImmunityBio narrative.

    Next Steps

    Sentiment around ImmunityBio is punchy right now, so it makes sense to move quickly, test the numbers yourself and weigh both sides of the story through 3 key rewards and 1 important warning sign.

    Looking for more ideas beyond ImmunityBio?

    If ImmunityBio has sharpened your focus, do not stop here. Cast the net wider and use fresh screeners to pressure test your next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.